Article
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
Vaccine - 8 May 2006
Polley Spencer D, Conway David J, Cavanagh David R, McBride Jana S, Lowe Brett S, Williams Thomas N, Mwangi Tabitha W, Marsh Kevin
Abstract excerpt
The merozoite surface protein (MSP) 2 is a vaccine candidate antigen of Plasmodium falciparum that is polymorphic in natural populations. In a prospective cohort study in two coastal populations of Kenya using recombinant proteins derived from the two major allelic types of MSP2, high serum levels of IgG to MSP2 were associated with protection from clinical malaria. This protection was independent of that...
Topics
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Alleles
- Animals
- Antibodies, Protozoan
- Antigens, Protozoan
- Child
- Child, Preschool
- Cohort Studies
- Humans
- Immunoglobulin G